| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/06/2006 | US20060073567 Novel insulin/IGF/relaxin family polypeptides and DNAs thereof |
| 04/06/2006 | US20060073522 Derived from ghrelin polypeptide, labelled with fluorochrome and cysteine; drug screening; high throughput assay |
| 04/06/2006 | US20060073333 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 04/06/2006 | US20060073215 Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough |
| 04/06/2006 | US20060073214 Colon cleansing composition and method |
| 04/06/2006 | US20060073196 Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier |
| 04/06/2006 | US20060073192 Composition and method for use in cartilage affecting conditions |
| 04/06/2006 | US20060073186 Nutritional compositions |
| 04/06/2006 | US20060073166 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR |
| 04/06/2006 | US20060073150 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers |
| 04/06/2006 | US20060073146 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 04/06/2006 | US20060073140 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 04/06/2006 | US20060073114 Compounds and methods to inhibit or augment an inflammatory response |
| 04/06/2006 | US20060073102 Abuse-resistant opioid solid dosage form |
| 04/06/2006 | CA2581980A1 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 04/06/2006 | CA2581927A1 Treatment or prevention of unscheduled bleeding in women on progestogen containing medication |
| 04/06/2006 | CA2581922A1 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof |
| 04/06/2006 | CA2581364A1 Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations |
| 04/06/2006 | CA2580798A1 Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs) |
| 04/05/2006 | EP1642975A2 Chemokine receptors 88-2B (CKR-3) and their antibodies |
| 04/05/2006 | EP1642974A1 Recombinant soluble Fc receptors |
| 04/05/2006 | EP1642968A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642967A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642907A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642906A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642596A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/05/2006 | EP1642594A1 Remedy for urinary tract diseases |
| 04/05/2006 | EP1642593A1 Solid pharmaceutical preparation |
| 04/05/2006 | EP1642591A1 MEDICINAL COMPOSITION CONTAINING NF-kAPPA B DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME |
| 04/05/2006 | EP1642581A2 Treatment of retinal diseases with quinoxaline derivatives |
| 04/05/2006 | EP1642576A2 Methods, kits and compositions for using pyrrole derivatives to combat anxiety |
| 04/05/2006 | EP1642574A2 Combination of a beta-2 adrenoceptor agonist and an aminosugar and their use for the treatment of immunomodulatory disorders |
| 04/05/2006 | EP1642573A1 Use of GABA B receptor modulators for treating gastro-intestinal disorders |
| 04/05/2006 | EP1641480A1 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| 04/05/2006 | EP1641479A2 Inhibition of stress-induced ligand-dependent egfr activation |
| 04/05/2006 | EP1641473A1 Buffered compositions for dialysis |
| 04/05/2006 | EP1641472A2 Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| 04/05/2006 | EP1641470A1 Vaginal compositions for treating pelvic tissue infections and traumas |
| 04/05/2006 | EP1641461A1 COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB>AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS |
| 04/05/2006 | EP1641455A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 04/05/2006 | EP1641453A2 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 04/05/2006 | EP1641449A1 Cancer treatment with epothilones |
| 04/05/2006 | EP1641443A1 Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema |
| 04/05/2006 | EP1641424A2 Programmed immune responses using a vaccination node |
| 04/05/2006 | EP1641352A1 Compositions for improved oxidative status in companion animals |
| 04/05/2006 | EP1411960B1 Fortified rice bran food product for promoting cardiovascular health |
| 04/05/2006 | EP1392308B1 Ophthalmically acceptable compositions comprising an alpha-2-adrenergic agonist and a fatty acid |
| 04/05/2006 | EP1351969A4 Method for generating immortal dendritic cell lines |
| 04/05/2006 | EP1320361A4 Method for reducing exacerbations associated with copd |
| 04/05/2006 | EP1307197B1 Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| 04/05/2006 | EP1198235A4 Method of promoting bone growth with hyaluronic acid and growth factors |
| 04/05/2006 | EP1147413B1 Growth differentiation factor inhibitors and uses therefor |
| 04/05/2006 | EP1140192B1 Use of the cyclooxygenase-2 inhibitor celecoxib and capecitabine for combination therapy in neoplasia |
| 04/05/2006 | EP0941364B1 Process aimed at evidencing the state of a malignant cell and process for treatment |
| 04/05/2006 | CN1756957A Method of detecting onset risk of encephalitis or encephalopathy |
| 04/05/2006 | CN1756567A Body weight gain inhibitor |
| 04/05/2006 | CN1756566A Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 04/05/2006 | CN1756554A Novel chemical entities and methods for their use in treatment of metabolic disorders |
| 04/05/2006 | CN1756549A Antineoplastic combinations comprising a rapamycin dderiovative and an aromatse inhibitor |
| 04/05/2006 | CN1756546A Microglia inhibitors for interrupting interleukin 12 and ifn-gamma-mediated immune reactions |
| 04/05/2006 | CN1756536A Composition and method for treating age-related disorders |
| 04/05/2006 | CN1756527A Regulation of mammalian hair growth |
| 04/05/2006 | CN1754574A Use of immune cell for treating blood coloboma symptom and arrest of bone marrow |
| 04/05/2006 | CN1249227C 真菌细胞壁合成基因 Fungal cell wall synthesis genes |
| 04/05/2006 | CN1249087C Novel human G-Protein coupled receptor |
| 04/05/2006 | CN1249061C Sulfonamide and sulfamide substituted imidazoquinolines and its pharmaceutical composition and uses |
| 04/05/2006 | CN1249055C Piperazinylcarbonylquinolines and -isoquinolines |
| 04/05/2006 | CN1249025C Aminobenzophenones as inhibiotors of IL-1 beta and TNF-alpha |
| 04/05/2006 | CN1248731C Combined application of tumor suppressor gene therapy and chemotherapy in preparation of pharmaceutical composition for treating tumor |
| 04/05/2006 | CN1248683C Treatment of type 2 diabetes mellitus using inhibitors of dipeptidyl peptidase IV |
| 04/04/2006 | US7022849 Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
| 04/04/2006 | US7022831 anticode oligomer treatments for inhibiting growth of cancer cells; complementary to mRNA |
| 04/04/2006 | US7022818 of given amino acid sequence; use as a target for drug screening of antagonists or agonists of said receptor; receptor can bind persephin |
| 04/04/2006 | US7022750 Anti-fouling coating containing copper and graphite |
| 04/04/2006 | US7022730 Protein tyrosine phosphatases inhibitors |
| 04/04/2006 | US7022712 Acidification of drugs such as carbendazim, by mixing with buffers improving water solubility; anticarcinogenic agents |
| 04/04/2006 | US7022709 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 04/04/2006 | US7022700 Neutropenia: oral administration |
| 04/04/2006 | US7022693 Treatment of lipodystrophy |
| 04/04/2006 | US7022687 for treatment of allergies and airway disorders such as allergic rhinitis |
| 04/04/2006 | US7022521 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 04/04/2006 | US7022495 Method for sorting antifungal molecules acting on the glucanosyltransferase activity |
| 04/04/2006 | US7022350 Dietary supplement |
| 04/04/2006 | US7022345 Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
| 04/04/2006 | US7022339 Antidiabetic preparation for oral administration |
| 04/04/2006 | US7022332 Sulfacetamide formulations for treatment of rosacea |
| 04/04/2006 | US7022322 Comprises ligand for human immunoglobulin for immunoapheresis, which mimicks sequence of an adrenergic receptor structure |
| 04/04/2006 | US7022315 Administering a thiol-based chemoprotectant agent intra-arterially for therapy and prophylaxis of side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck |
| 04/04/2006 | US7022313 Hydrogel particle formulation |
| 04/04/2006 | US7022312 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 04/04/2006 | US7022064 Cardiac support with controlled ventricular pressure |
| 04/04/2006 | CA2379521C Methods to identify compounds that modulate rage |
| 04/04/2006 | CA2103022C Improvements in benzodiazepine treatment by cholinesterase inhibitors |
| 03/30/2006 | WO2006033734A2 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| 03/30/2006 | WO2006033453A1 Activity enhancer for interferon agent |
| 03/30/2006 | WO2006033412A1 Alleviator for radiation disorder |
| 03/30/2006 | WO2006033296A1 Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
| 03/30/2006 | WO2006033287A1 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE |
| 03/30/2006 | WO2006032908A1 Bioreductively-activated prodrugs |
| 03/30/2006 | WO2005123132A3 Use of liver-selective glucokinase activators |